Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Regeneus Ltd. ( (AU:CMB) ) is now available.
Cambium Bio Limited has successfully updated its placement participant list following a fully-subscribed capital raise of A$2.17 million. The funds will be directed towards Phase 3 clinical trials for Elate Ocular®, a treatment for dry eye disease, and for working capital. Notable investors include representatives from Da Jyun Capital Investment Corporation and directors from MetaTech and Locus Cell Co. Ltd. This capital injection is expected to bolster Cambium Bio’s efforts in advancing its clinical pipeline and strengthening its market position in regenerative medicine.
More about Regeneus Ltd.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company’s proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio’s lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company’s stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 12,708
Technical Sentiment Signal: Sell
Current Market Cap: A$6.58M
See more data about CMB stock on TipRanks’ Stock Analysis page.